Twiggy's Invex Therapeutics | The Imminent Coin Flip, page-3

The Chart: An Opportunity at these Levels?

Timeline Annotations of the IXC Chart Story Thus Far

- IXC IPO'd in mid 2019 with Phase II data due Mid 2020, stock performs very well on IPO with tight T20
- The stock rose in anticipation for the Mid 2020 Phase II data read out in early 2020
- Before crashing alongside the Covid 19 Market Crash Hysteria in March 2020
- It quickly rerated into a Positive Phase II Data Readout in April/May 2020
- $26M was raised at $1.30, with Andrew Twiggy Forrest Investing as a cornerstone investor in June 2020
- Initial FDA advice required different primary endpoints than the EMA for EU/UK/AU markets, investors sell due to uncertainty in late 2020
- IXC management decide to pursue the CUV strategy, a company that had a similar situation occur, Mid 2021
- Phase III strategy targets EU/UK/AU markets through an EMA only trial as its the least risk approach for a $1B TAM Market
- Phase III data will then be used for US FDA negotiations for approval or a smaller Phase III trial for a $600M TAM Market
- Stock starts climbing leading into Phase III start in early Jan 2022
- Ukraine War hits, coinciding with interest rate raises globally in March of 2022
- Indexes wipe out -25-30% (S&P500 and Nasdaq, with growth assets with catalysts far out rerating lower) IXC slides alongside
- Phase III is launched with CUV strategy with first patient recruited in late November 2023, to no movement in SP
- Rates continue to rise, stock market continues to deepen, Retail sentiment at all time low, resulting in a sell off to Covid 19 Lows
- All required licenses and ethics approvals in place for Phase III, fully funded reiterated in latest call.
- All Systems go!